URGN — UroGen Pharma Ltd.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1668243 ·
Last close
$29.87
Market Cap
$1.47B
52W High
$50.81
52W Low
$16.50
ADV30
1,415,687
Next earnings
2026-11-04

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 89,001,000 81,499,000 8,329,000 -1,462,000 271,873,000 85,564,000 397,090,000
Jun 2026 72,456,000 65,884,000 111,000 -14,351,000 252,590,000 79,133,000 384,986,000
Mar 2026 50,959,000 46,820,000 -20,263,000 -23,574,000 253,690,000 109,968,000 377,943,000
Dec 2025 37,837,000 34,548,000 -19,115,000 -26,364,000 200,455,000 110,745,000 305,929,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-131,846,000
Investing CF
$28,556,000
Financing CF
$98,798,000
CapEx
$-203,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.32
As of
2026-11-08

Balance + Analyst (yfinance extras)

Retained Earnings
$-999,103,000
Inventory
$25,150,000
Receivables
$117,283,000
ST Investments
$4,985,000
EBIT TTM
$-46,473,000
Pretax Income TTM
$-64,153,000
Interest Exp TTM
$17,680,000
Analysts
7

Yahoo Snapshot (yfinance, live)

Total Revenue
$250,252,992
EBITDA
$-30,629,000
Free Cash Flow
$-97,182,248
Enterprise Value
$1,319,667,584
Total Cash
$90,549,000
Total Debt
$196,283,008
Shares Out
49,047,823
Trailing EPS
$-1.31
Book Value
$-2.55
ROE
—
ROA
-8.5%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 109,788,000 -124,863,000 -153,494,000 200,455,000 305,929,000 -105,474,000 -162,444,000
Dec 2024 90,398,000 -96,782,000 -126,874,000 285,711,000 294,514,000 -8,803,000 -96,766,000
Dec 2023 82,713,000 -65,536,000 -102,244,000 178,311,000 243,523,000 -65,212,000 -76,376,000
Dec 2022 64,357,000 -79,041,000 -109,783,000 135,619,000 224,980,000 -89,361,000 -87,559,000

TTM Snapshot

Revenues TTM
$188,734,000
NetIncome TTM
$-97,636,000
OpCashFlow TTM
—
Assets (Latest)
$252,590,000
Forward EPS
$2.80

Max Pain — expiry 2027-01-15 (volume-derived — Yahoo OI feed degraded)

max pain strike: $25.00 · spot: $29.79 · call volume: 275 · put volume: 322
Expected Move to 2027-01-15: ±$4.90 (16.45%) — implied range $24.89 – $34.69 · ATM straddle on $30.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
QURE uniQure N.V. $1.46B $20.78 —
PCRX Pacira BioSciences, Inc. $1.46B $36.48 —
KRSA Korsana Biosciences, Inc. $1.48B $32.50 —
RAPP Rapport Therapeutics, Inc. $1.41B $23.76 —
ADRX ADARx Pharmaceuticals, Inc. $1.53B $13.82 —

News headlines (Yahoo Finance, 1h cache)

UroGen Pharma (URGN) Stock Could Be A Bargain Following Its 148% Run
2026-11-18 00:24 · Yahoo
UroGen Pharma Ltd (URGN) (Q3 2026) Earnings Call Highlights: Zysturi's 35% Sequential Surge and ...
2026-11-05 03:09 · Yahoo
Earnings Beat Might Change The Case For Investing In UroGen Pharma (URGN)
2026-11-05 01:13 · Yahoo
Urogen Pharma Q3 Earnings Call Highlights
2026-11-04 22:14 · Yahoo
The Gel That Became a Business
2026-11-04 21:50 · Yahoo
UroGen (URGN) Q3 2026 Earnings Call Transcript
2026-11-04 20:14 · Yahoo
Urogen Pharma (URGN) Reports Q3 Loss, Beats Revenue Estimates
2026-11-04 14:05 · Yahoo
UroGen Reports $68.0 Million of ZUSDURI Revenue and Provides Third Quarter 2026 Financial Results and Highlights
2026-11-04 13:00 · Yahoo
UroGen Pharma to Present at the Guggenheim Securities 3rd Annual Healthcare Innovation Conference
2026-11-03 13:00 · Yahoo
UroGen’s Final Results from Olympus Five-Year Follow-Up Study Reinforces Durable Response with JELMYTO in Patients with Low-Grade Upper Tract Urothelial Cancer
2026-10-28 12:00 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.